Urinary type IV collagen excretion predicts an increased urinary albumin-to-creatinine ratio in normoalbuminuric patients with diabetes

Susumu Ogawa, Masato Matsushima, Masashi Okamura, Miho Senda, Takuya Sakamoto, Kazuhiro Nako, Sadayoshi Ito

Division of Clinical Epidemiology, Jikei University School of Medicine, Tokyo, Japan.
Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Hospital, Sendai, Japan.

DOI: 10.4236/jdm.2012.24065                

Abstract

Aims: We evaluated whether urinary excretion of type IV collagen (U-COL) may predict an increase in the urinary albumin-to-creatinine ratio (ACR) and what factors regulate U-COL in 145 normoalbuminuric patients with type 2 diabetes. Methods: We measured HbA1c, systolic blood pressure (SBP), urinary 8-hydroxydeoxyguanosine (8-OHdG) and monocyte chemoattractant protein (MCP)-1 at start of this study (Baseline), ACR and U-COL in addition to these measurements at one year later (Evaluation-1), and ACR and SBP after two years of the Evaluation-1 (Evaluation-2). The relationships were investigated between the increase of ACR and the U-COL. The effect of angiotensin receptor blockers (ARB) treatment on the correlations between U-COL and ACR at Evaluation-2 on one hand, and between U-COL and percent change of ACR on the other, was also analyzed. Furthermore, we investigated whether the increase in 8-OHdG and in MCP-1 in a year prior to the Evaluation-1 were risk factors of the rise in U-COL levels. Results: Both U-COL and SBP at Evaluation-1, but not ARB treatment, were independent risk factors for an increased ACR after 2 years. ARB treatment significantly suppressed the increase in ACR after 2 years in patients with higher U-COL excretion. The percentage changes in 8-OHdG (%8-OHdG) and MCP-1 (%MCP-1) in one year prior to Evaluation-1 measurements are independent risk factors for U-COL. HbA1c and SBP values one year prior to Evaluation-1 are independent risk factors not only for %8-OHdG but also, for baseline U-COL. The %8-OHdG is an independent risk factor for %MCP-1. Conclusions: U-COL may predict an increase in the ACR. The U-COL seems to be increased with oxidative stress and inflammation induced by past hyperglycemia.

Keywords

Type IV Collagen; Diabetic Nephropathy; Oxidative Stress; Monocyte Chemoattractant Protein-1

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Moriya, T., Tanaka, K. and Moriya, R. (2000) Glomerular structural changes and structural-functional relationships at early stage of diabetic nephropathy in Japanese type 2 diabetic patients. Medical Electron Microscopy, 33, 115-122. doi:10.1007/s007950000010
[2]	Moriya, T., Tanaka, K., Hosaka, T., Hirasawa, Y. and Fujita, Y. (2008) Renal structure as an indicator for development of albuminuria in normo- and micro-albuminuric type 2 diabetic patients. Diabetes Research and Clinical Practice, 82, 298-304. doi:10.1016/j.diabres.2008.08.015
[3]	Ziyadeh, F.N. and Wolf, G. (2008) Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Current Diabetes Reviews, 4, 39-45. doi:10.2174/157339908783502370
[4]	Okonogi, H., Nishimura, M., Utsunomiya, Y., Hamaguchi, K., Tsuchida, H., Miura, Y., Suzuki, S., Kawamura, T., Hosoya, T. and Yamada, K. (2001) Urinary type IV collagen excretion reflects renal morphological alterations and type IV collagen expression in patients with type 2 diabetes mellitus. Clinical Nephrology, 55, 357-364.
[5]	Cohen, M.P., Shearman, C.W. and Lautenslager, G.T. (2001) Serum type IV collagen in diabetic patients at risk for nephropathy. Diabetes Care, 24, 1324-1327. doi:10.2337/diacare.24.8.1324
[6]	Cohen, M.P., Lautenslager, G.T. and Shearman, C.W. (2001) Increased urinary type IV collagen marks the development of glomerular pathology in diabetic d/db mice. Metabolism, 50, 1435-1440. doi:10.1053/meta.2001.28074
[7]	Cohen, M.P., Lautenslager, G.T. and Shearman, C.W. (2001) Increased collagen IV excretion in diabetes. A marker of compromised filtration function. Diabetes Care, 24, 914-918. doi:10.2337/diacare.24.5.914
[8]	Elmarakby, A.A. and Sullivan, J.C. (2012) Relationship between Oxidative Stress and Inflammatory Cytokines in Diabetic Nephropathy. Cardiovascular Therapeutics, 30, 49-59. doi:10.1111/j.1755-5922.2010.00218.x
[9]	Wu, J., Mei, C., Vlassara, H., Striker, G.E. and Zheng, F. (2009) Oxidative stress-induced JNK activation contributes to proinflammatory phenotype of aging diabetic mesangial cells. American Journal of Physiology, 297, F1622-F1631. doi:10.1152/ajprenal.00078.2009
[10]	Lee, H.B., Yu, M.R., Yang, Y., Jiang, Z. and Ha, H. (2003) Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. Journal of the American Society of Nephrology, 14, S241-245. doi:10.1097/01.ASN.0000077410.66390.0F
[11]	Ogawa, S., Kobori, H., Ohashi, N., Urushihara, M., Nishiyama, A., Mori, T., Ishizuka, T., Nako, K. and Ito, S. (2009) Angiotensin II Type 1 Receptor Blockers Reduce Urinary Angiotensinogen Excretion and the Levels of Urinary Markers of Oxidative Stress and Inflammation in Patients with Type 2 Diabetic Nephropathy. Biomarker Insights, 4, 97-102.
[12]	Ogawa, S., Mori, T., Nako, K., Kato, T., Takeuchi, K. and Ito, S. (2006) Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension, 47, 699-705. doi:10.1161/01.HYP.0000203826.15076.4b
[13]	Araki, S., Haneda, M., Koya, D., Isshiki, K., Kume, S., Sugimoto, T., Kawai, H., Nishio, Y., Kashiwagi, A., Uzu, T. and Maegawa, H. (2010) Association between urinary type IV collagen level and deterioration of renal function in type 2 diabetic patients without overt proteinuria. Diabetes Care, 33, 1805-1810. doi:10.2337/dc10-0199
[14]	Taft, J.L., Nolan, C.J., Yeung, S.P., Hewitson, T.D. and Martin, F.I. (1994) Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes, 43, 1046-1051. doi:10.2337/diabetes.43.8.1046
[15]	Watanabe, H., Sanada, H., Shigetomi, S., Katoh, T. and Watanabe, T. (2000) Urinary excretion of type IV collagen as a specific indicator of the progression of diabetic nephropathy. Nephron, 86, 27-35. doi:10.1159/000045709
[16]	Morii, T., Fujita, H., Narita, T., Shimotomai, T., Fujishima, H., Yoshioka, N., Imai, H., Kakei, M. and Ito, S. (2003) Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. Journal of Diabetes and Its Complications, 17, 11-15. doi:10.1016/S1056-8727(02)00176-9
[17]	Banba, N., Nakamura, T., Matsumura, M., Kuroda, H., Hattori, Y. and Kasai, K. (2000) Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney International, 58, 684-690. doi:10.1046/j.1523-1755.2000.00214.x
[18]	Vlek, A.L., van der, Graaf. Y., Braam, B., Moll, F.L., Nathoe, H.M. and Visseren, F.L., SMART Study Group (2009) Blood Pressure and Decline in Kidney Function in Patients With Atherosclerotic Vascular Disease: A Cohort Study. American Journal of Kidney Diseases, 54, 820-829. doi:10.1053/j.ajkd.2009.07.007
[19]	Kotajima, N., Kimura, T., Kanda, T., Obata, K., Kuwabara, A., Fukumura, Y. and Kobayashi, I. (2000) Type IV collagen as an early marker for diabetic nephropathy in non-insulindependent diabetes mellitus. Journal of Diabetes and Its Complications, 14, 13-17. doi:10.1016/S1056-8727(00)00064-7
[20]	Lee, H.S. (2012) Mechanisms and consequences of TGF-? overexpression by podocytes in progressive podocyte disease. Cell and Tissue Research, 347, 129-140. doi:10.1007/s00441-011-1169-7
[21]	Cohen, M.P., Lautenslager, G.T. and Shearman, C.W. (2001) Increased collagen IV excretion in diabetes. A marker of compromised filtration function. Diabetes Care, 24, 914-918. doi:10.2337/diacare.24.5.914
[22]	Tomino, Y., Suzuki, S., Azushima, C., Shou, I., Iijima, T., Yagame, M., Wang, L.N., Chen, H.C., Lai, K.N., Tan, S.Y. and Kim, M.J. (2001) Asian multicenter trials on urinary type IV collagen in patients with diabetic nephropathy. Journal of Clinical Laboratory Analysis, 15, 188-192. doi:10.1002/jcla.1026
[23]	Kado, S., Aoki, A., Wada, S., Katayama, Y., Kugai, N., Yoshizawa, N. and Nagata, N. (1996) Urinary type IV collagen as a marker for early diabetic nephropathy. Diabetes Research and Clinical Practice, 31, 103-108. doi:10.1016/0168-8227(96)01210-7
[24]	Doi, T., Mima, A., Matsubara, T., Tominaga, T., Arai, H. and Abe, H. (2008) The current clinical problems for early phase of diabetic nephropathy and approach for pathogenesis of diabetic nephropathy. Diabetes Research and Clinical Practice, 82, S21-S24. doi:10.1016/j.diabres.2008.09.013
[25]	Mima, A., Arai, H., Matsubara, T., Abe, H., Nagai, K., Tamura, Y., Torikoshi, K., Araki, M., Kanamori, H., Takahashi, T., Tominaga, T., Matsuura, M., Iehara, N., Fukatsu, A., Kita, T. and Doi, T. (2008) Urinary Smad1 is a novel marker to predict later onset of mesangial matrix expansion in diabetic nephropathy. Diabetes, 57, 1712-1722. doi:10.2337/db07-1726
[26]	Matsubara, T., Abe, H., Arai, H., Nagai, K., Mima, A., Kanamori, H., Sumi, E., Takahashi, T., Matsuura, M., Iehara, N., Fukatsu, A., Kita, T. and Doi, T. (2006) Expression of Smad1 is directly associated with mesangial matrix expansion in rat diabetic nephropathy. Laboratory Investigation, 86, 357-368. doi:10.1038/labinvest.3700400
[27]	Abe, H., Matsubara, T., Iehara, N., Nagai, K., Takahashi, T., Arai, H., Kita, T. and Doi, T. (2004) Type IV collagen is transcriptionally regulated by Smad1 under advanced glycation end product (AGE) stimulation. The Journal of Biological Chemistry, 279, 14201-14206. doi:10.1074/jbc.M310427200
[28]	Lee, E.Y., Chung, C.H., Khoury, C.C., Yeo, T.K., Pyagay, P.E., Wang, A. and Chen, S. (2009) The monocyte chemo-attractant protein-1/CCR2 loop, inducible by TGF-beta, increases podocyte motility and albumin permeability. American Journal of Physiology—Renal Physiology, 297, F85-F94. doi:10.1152/ajprenal.90642.2008
[29]	Park, J., Ryu, D.R., Li, J.J., Jung, D.S., Kwak, S.J., Lee, S.H., Yoo, T.H., Han, S.H., Lee, J.E., Kim, D.K., Moon, S.J., Kim, K., Han, D.S. and Kang, S.W. (2008) MCP-1/ CCR2 system is involved in high glucose-induced fibronectin and type IV collagen expression in cultured mesangial cells. American Journal of Physiology—Renal Physiology, 295, F749-F757. doi:10.1152/ajprenal.00547.2007
[30]	Nam, B.Y., Paeng, J., Kim, S.H., Lee, S.H., Kim, do. H., Kang, H.Y., Li, J.J., Kwak, S.J., Park, J.T., Yoo, T.H., Han, S.H., Kim, D.K. and Kang, S.W. (2012) The MCP-1/ CCR2 axis in podocytes is involved in apoptosis induced by diabetic conditions. Apoptosis, 17, 1-13. doi:10.1007/s10495-011-0661-6
[31]	Lagranha, C.J., Fiorino, P., Casarini, D.E., Schaan, B.D. and Irigoyen, M.C.(2007) Molecular bases of diabetic nephropathy. Arquivos Brasileiros de Endocrinologia & Metabologia, 51, 901-912. doi:10.1590/S0004-27302007000600003
[32]	Sanchez, A.P. and Sharma, K. (2009)Transcription factors in the pathogenesis of diabetic nephropathy. Expert Rev Mol Med, 11, e13. doi:10.1017/S1462399409001057
[33]	Mima, A., Matsubara, T., Arai, H., Abe, H., Nagai, K., Kanamori, H., Sumi, E., Takahashi, T., Iehara, N., Fukatsu, A., Kita, T. and Doi, T. (2006) Angiotensin II-dependent Src and Smad1 signaling pathway is crucial for the development of diabetic nephropathy. Laboratory Investigation, 86, 927-939. doi:10.1038/labinvest.3700445
[34]	Haller, H., Ito, S., Izzo, J.L. Jr., Januszewicz, A., Katayama, S., Menne, J., Mimran, A., Rabelink, T.J., Ritz, E., Ruilope, L.M., Rump, L.C. and Viberti, G., ROADMAP Trial Investigators (2011) Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes. The New England Journal of Medicine, 364, 907-917. doi:10.1056/NEJMoa1007994
[35]	Ruggenenti, P., Fassi, A., Ilieva, A.P., Bruno, S., Iliev, I.P., Brusegan, V., Rubis, N., Gherardi, G., Arnoldi, F., Ganeva, M., Ene-Iordache, B., Gaspari, F., Perna, A., Bossi, A., Trevisan, R., Dodesini, A.R. and Remuzzi, G., Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators (2004) Preventing microalbuminuria in type 2 diabetes. The New England Journal of Medicine, 351, 1941-1951. doi:10.1056/NEJMoa042167